- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03643042
Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome (SMD-transfu)
Impact of 2 Transfusion Strategies on the Quality of Life of Multi-transfused Patients With Low Risk Myelodysplastic Syndrome: Multicenter Randomized Trial Comparing a Liberal vs. Restrictive Transfusion Regimen
Myelodysplastic syndromes (MDS) are heterogeneous malignant bone marrow disorders characterized by ineffective haematopoiesis, peripheral blood cytopenias and variable risk of leukaemia transformation.
Anemia is the most common manifestation of bone marrow failure in MDS. After failure with first-line treatment by Erythropoietin, patients survive in average 5 years under long term blood transfusion. Modalities of blood transfusion are not clearly defined.
Then, the objective of this randomized comparative multicentric study is to compare two modalities of threshold for transfusion:
- Restrictive group: Hb < 80g/L and Hb maintain between 80 and 100g/L
- Liberal group: Hb < 100g/L and Hb maintain between 100 and 120g/L
Study Overview
Status
Intervention / Treatment
Detailed Description
Myelodysplastic syndromes (MDS) are heterogeneous malignant bone marrow disorders characterized by ineffective haematopoiesis, peripheral blood cytopenias and variable risk of leukaemia transformation. The median age at diagnosis is 75 years. The incidence is about 30 per 100,000, over 70 years. Etiology is unknown in more than 85% of cases, chemo-induced causes and family cases are well individualized.
Diagnosis, prognosis, and classification (WHO) are based on joint cytologic analysis of peripheral blood, bone marrow, and spinal cytogenetic analysis. The main therapeutic objectives in low-risk MDS are to correct cytopenias, improve quality of life and prevent aggravation of co-morbidities.
Anemia is the most common manifestation of bone marrow failure in MDS. It is encountered in 80% of cases at diagnosis and almost always occurs in the progression of the disease. Its presence and importance have a pejorative prognostic value, but it is not clear whether this anemia is indicative of a more serious clonal disease or whether it is the repercussions of anemia that lead to a more severe prognosis. After failure with first-line treatment by Erythropoietin (EPO), patients survive in average 5 years under long term blood transfusion. Modalities of blood transfusion are not clearly defined.
Studies in the general geriatric population and in cases of acute anemia are in favor of a restrictive transfusion regimen (threshold around 70 g/L), while experience during MDS with EPO suggest that maintaining a higher hemoglobin count could have a favorable impact on quality of life, physical performance, or even survival of patients with MDS.
Then, the objective of this randomized comparative multicentric study is to compare two modalities of threshold for transfusion:
- Restrictive group: Hb < 80g/L and Hb maintain between 80 and 100g/L
- Liberal group: Hb < 100g/L and Hb maintain between 100 and 120g/L
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Abbeville, France, 80142
- Abbeville CH
-
Amiens, France, 80054
- Amiens CHU
-
Arras, France, 62000
- Arras CH
-
Avignon, France, 84000
- Henri Duffaut CH
-
Besançon, France, 25030
- Besançon CHU
-
Bordeaux, France, 33604
- Bordeaux CHU
-
Caen, France, 14033
- Cote de Nacre CHU
-
Clermont-Ferrand, France, 63000
- Clermont-Ferrand CHU
-
Dunkerque, France, 59140
- Dunkerque CH
-
Grenoble, France, 38043
- Grenoble CHU
-
Le Mans, France, 72037
- Le Mans CH
-
Lens, France, 62307
- Lens CH
-
Lille, France, 59020
- St-Vincent Hospital
-
Limoges, France, 87042
- Limoges CHRU
-
Meaux, France, 77104
- Meaux CH
-
Nice, France, 06202
- Archet 1 Hospital
-
Paris, France, 75475
- Saint-Louis Hospital, APHP
-
Rennes, France, 35033
- Pontchaillou Hospital
-
Roubaix, France, 59100
- roubaix CH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with low risk or intermediate risk MDS: Revised International Prognostic Scoring System (IPSS-R) less than or equal to 4.5
- Relapse or failure after Erythropoiesis-Stimulating Agent (ESA) therapy or others treatments (Lenalidomide, Thalidomide, 5-Azacytidine, antithymocyte globulin (ATG), Luspatercept, Decitabine, allograft)
- Transfusion dependent: in average at least 3 transfusion episodes in the last 6 months and total of packed red blood cells (PRBC): more than 8 in the last 12 months and less than 150 in total.
- ≥ 18 years of age
- The Eastern Cooperative Oncology Group (ECOG) score < 4
- Life expectancy > 12 Months
- Patients willing to participate in the study and who have signed the informed consent form
Exclusion Criteria:
- Patients with disease modifying agents for their MDS such as: ESA therapy, Lenalidomide, Thalidomide revlimid, Vidaza, Allograft, antithymocyte globulin (ATG), Luspatercept, Decitabine, experimental agents, other clinical trial, taken within 3 months prior to inclusion (chelators are accepted)
- According to physician: unable to tolerate restrictive or liberal red cell transfusion thresholds (e.g. clinically significant cardio-respiratory failure)
- Cognitive alteration (inability to complete QUALMS)
- Inability to perform the physical performance test Timed up and go test
- Splenomegaly > 3 cm below the costal margin
- Severe renal failure with creatinine clearance < 30ml / min
- Patients presenting with active bleeding or evidence of significant haemolysis
- Patient under guardianship or curatorship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Restrictive group
Transfusion with: Hb < 80g/L and Hb maintain between 80 and 100g/L
|
Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
|
Experimental: Liberal group
Transfusion with: Hb < 100g/L and Hb maintain between 100 and 120g/L
|
Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life by Myelodysplasia Scale (QUALMS) score
Time Frame: six months post-randomization
|
Quality of Life assessed by a specific validated and adapted disease scale :Quality of Life by Myelodysplasia Scale (QUALMS) score at six months post-randomization.
The QUALMS consists of 38 items, and takes less than 10 minutes to complete.
Scored on a scale of 0 to 100 higher score is correlated with better MDS-specific quality of life.
|
six months post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life by Myelodysplasia Scale (QUALMS) score over the twelve months of follow-up
Time Frame: 3, 6, 12 Months
|
Evolution of the QUALMS score over the twelve months of follow-up.
Scored on a scale of 0 to 100 higher score is correlated with better MDS-specific quality of life.
|
3, 6, 12 Months
|
Timed up and go test over the twelve months of follow-up
Time Frame: 3, 6, 12 Months
|
Evolution of physical performance (the time required for the Timed up and go test) at six months post-randomization and over the twelve months of follow-up
|
3, 6, 12 Months
|
Transfusion incidents rate over the twelve months of follow-up
Time Frame: 3, 6, 12 Months
|
Transfusion incidents rate during the twelve months of follow-up among allo-immunization, hospitalization for pulmonary overload, iron overload (ferritin, transferrin saturation), TRALI (Transfusion-Related Acute Lung Injury)
|
3, 6, 12 Months
|
Transfusion costs over the twelve months of follow-up
Time Frame: 3, 6, 12 Months
|
Transfusion costs (number of Packed red blood cells (PRBC) used) during the twelve months of follow-up
|
3, 6, 12 Months
|
Time of occurrence of diagnosis of heart and liver damage due to transfusional iron overload over twelve months of follow-up
Time Frame: 3, 6, 12 Months
|
Time of occurrence of diagnosis of heart and liver damage due to transfusional iron overload over twelve months of follow-up.
The diagnosis will be established according to the standard procedure based on annual MRI, in particular by measuring the LIC (liver iron concentration), the MIC (myocardial iron concentration) and the cardiac T2* value.
|
3, 6, 12 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Laurent Pascal, MD, GHICL
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC-P0071
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on Transfusion
-
National Institutes of Health Clinical Center (CC)Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedMyocardial Infarction | Anemia | Blood TransfusionSpain, France
-
Hamad Medical CorporationSidra Medical and Research Center; World Anti-Doping Agency; Anti-Doping Lab... and other collaboratorsUnknownBlood Disease | Blood Transfusion, Autologous | Blood Doping | Blood Transfusion, HomologousQatar
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical UniversityWithdrawnAnemia | Necrotizing Enterocolitis | Red Blood Cell (RBC) TransfusionChina
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia | Primary Myelofibrosis | Thrombocytopenia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Venous Thromboembolism | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient | Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditionsUnited States
-
Chang Gung Memorial HospitalCompletedTrauma Patients Received Blood Transfusion ≥ 10 U | Trauma Patients Had Not Received Blood Transfusion ≥ 10 UTaiwan
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsRecruitingThe Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy VolunteersFrance
-
Hospital PitangueirasUnknown
-
Unity Health TorontoRecruitingCardiac Surgery | Heart | Postoperative | DisorderCanada, Russian Federation
-
Haukeland University HospitalDentsply Sirona Implants and ConsumablesCompleted